

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Maruani et al.

Serial No.: 10/044,531

Filed: 1/11/02

Group Art Unit: 1617

Examiner: Jennifer M. Kim

FOR: USE OF CENTRAL CANNABINOID
RECEPTOR ANTAGONISTS FOR THE
PREPARATION OF DRUGS**CERTIFICATE UNDER 37 C.F.R. 1.8(a)**

I hereby certify that this correspondence is being deposited on the date indicated below with the United States Postal Service as first class mail addressed to: Commissioner for Patents, Washington, D.C. 20231

Name

Date

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

RESPONSE TO RESTRICTION REQUIREMENT

This is in response to the Office Action mailed on March 25, 2003 by the United States Patent and Trademark Office setting a one month period for response which was set to expire on April 25, 2003.

Claims 19-33 and 39 are pending in the application.

Restriction has been required under 35 U.S.C. §121 as follows:

Group I: Claims 19-29 and 39 drawn to a pharmaceutical composition.


Group II: Claims 30-33 drawn to a kit for the treatment of appetency disorders

Applicants hereby provisionally elect, with traverse, the subject matter of Group I, Claims 19-29 and 39.

The restriction requirement is traversed and reconsideration and modification thereof are requested because claims 19-29 and 39 which cover pharmaceutical compositions and claims 30-33 which cover a kit for the treatment of appetency disorders, are simply different aspects of the same inventive concept and should, therefore, be considered a single invention and not "two or more independent and distinct inventions" within the meaning of 35 U.S.C. §121.

Respectfully submitted,

Date: April 1, 2002



Michael D. Alexander
Reg. No. 36,080

Address:
Sanofi-Synthelabo Inc.
9 Great Valley Parkway
P.O. Box 3026
Malvern, PA 19355
Tele: (610) 889-8802
Fax: (610) 889-8799